1. Reversal of ABCG2/BCRP-Mediated Multidrug Resistance by 5,3′,5′-Trihydroxy-3,6,7,4′-tetramethoxyflavone Isolated from the Australian Desert Plant Eremophila galeata Chinnock
- Author
-
Malene J. Petersen, Bevan Buirchell, Michael Gajhede, Jan Stenvang, Kenneth T. Kongstad, Dan Staerk, Henrik Franzyk, Xamuel L Lund, Susan J. Semple, Petersen, Malene J, Lund, Xamuel L, Semple, Susan J, Buirchell, Bevan, Franzyk, Henrik, Gajhede, Michael, Kongstad, Kenneth T, Stenvang, Jan, and Staerk, Dan
- Subjects
Eremophila galeata ,Abcg2 ,eremophila galeata ,Abcg2 bcrp ,Pharmacology ,Irinotecan ,Biochemistry ,Microbiology ,Article ,chemistry.chemical_compound ,Eremophila Plant ,multidrug resistance ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Humans ,Molecular Biology ,Flavonoids ,biology ,Chemistry ,Eremophila ,Drug Synergism ,biology.organism_classification ,Breast cancer resistance protein ,QR1-502 ,Drug Resistance, Multiple ,Cancer treatment ,Neoplasm Proteins ,Multiple drug resistance ,Gene Expression Regulation, Neoplastic ,Docking (molecular) ,Drug Resistance, Neoplasm ,breast cancer resistance protein ,Colonic Neoplasms ,docking ,biology.protein ,Efflux ,Growth inhibition ,HT29 Cells - Abstract
Multidrug resistance (MDR) is a major challenge in cancer treatment, and the breast cancer resistance protein (BCRP) is an important target in the search for new MDR-reversing drugs. With the aim of discovering new potential BCRP inhibitors, the crude extract of leaves of Eremophila galeata, a plant endemic to Australia, was investigated for inhibitory activity of parental (HT29par) as well as BCRP-overexpressing HT29 colon cancer cells resistant to the chemotherapeutic SN-38 (i.e., HT29SN38 cells). This identified a fraction, eluted with 40% acetonitrile on a solid-phase extraction column, which showed weak growth-inhibitory activity on HT29SN38 cells when administered alone, but exhibited concentration-dependent growth inhibition when administered in combination with SN-38. The major constituent in this fraction was isolated and found to be 5,3′,5′-trihydroxy-3,6,7,4′-tetramethoxyflavone (2), which at a concentration of 25 μg/mL potentiated the growth-inhibitory activity of SN-38 to a degree comparable to that of the known BCRP inhibitor Ko143 at 1 μM. A dye accumulation experiment suggested that 2 inhibits BCRP, and docking studies showed that 2 binds to the same BCRP site as SN-38. These results indicate that 2 acts synergistically with SN-38, with 2 being a BCRP efflux pump inhibitor while SN-38 inhibits topoisomerase-1.
- Published
- 2021
- Full Text
- View/download PDF